What is Acorai?
Acorai is at the forefront of developing advanced medical technology designed to revolutionize heart failure management. Their flagship product, the SAVE Sensor System, is a sophisticated multi-modal platform employing seismic, acoustic, visual, and electric sensors. This system provides healthcare professionals with accurate, absolute insights into intracardiac pressures, a critical factor in identifying hemodynamic congestion and tailoring patient therapy. Clinically validated in over 2000 patients, the Acorai Heart Monitor offers actionable data to enhance patient outcomes and advance cardiac care through strategic collaborations with leading healthcare partners.
How much funding has Acorai raised?
Acorai has raised a total of $17.6M across 3 funding rounds:
Grant
$10.7M
Grant
$2.4M
Angel/Seed
$4.5M
Grant (2023): $2.4M with participation from The European Innovation Council
Grant (2023): $10.7M led by The European Innovation Council
Angel/Seed (2024): $4.5M supported by CARMA FUND Management
Key Investors in Acorai
CARMA FUND Management
CARMA FUND Management is an early-stage investment fund focused on advancing Life Science and Healthcare technologies, providing flexible investment modes and industry partnerships to support young companies in the medical space.
The European Innovation Council
The European Innovation Council is an entity supporting innovation, likely focusing on advancing cutting-edge technologies within the European Union, particularly in sectors like MedTech and healthcare.
The European Innovation Council
The European Innovation Council is an entity supporting innovation, likely focusing on advancing cutting-edge technologies within the European Union, particularly in sectors like MedTech and healthcare.
What's next for Acorai?
With the recent major strategic investment, Acorai is poised for accelerated growth and market expansion. The substantial capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the commercial reach of their non-invasive cardiac pressure sensing technology. This funding round signals a critical phase for the company, enabling them to scale operations and solidify their position as a key innovator in the MedTech sector, particularly in the critical area of heart failure management. The focus will likely be on clinical adoption and demonstrating the long-term value of their personalized therapy solutions.
See full Acorai company page
